Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure

被引:124
作者
Petersson, M [1 ]
Friberg, P
Eisenhofer, G
Lambert, G
Rundqvist, B
机构
[1] Sahlgrens Univ Hosp, Cardiovasc Inst, Dept Cardiol, S-41345 Gothenburg, Sweden
[2] Sahlgrens Univ Hosp, Cardiovasc Inst, Dept Clin Physiol, S-41345 Gothenburg, Sweden
[3] NINDS, Clin Neurocardiol Sect, NIH, Bethesda, MD 20892 USA
[4] Baker Heart Res Inst, Melbourne, Vic, Australia
关键词
heart failure; congestive; survival analysis; sympathetic nervous system; noradrenatine; renal circulation;
D O I
10.1093/eurheartj/ehi184
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Although cardiac sympathetic activation is associated with adverse outcome in patients with chronic heart failure (CHF), the influence of renal sympathetic activity on outcome is unknown. We assessed the hypothesis that renal noradrenaline (NA) spillover is a predictor of the combined endpoint of all-cause mortality and heart transplantation in CHF. Methods and results Sixty-one patients with CHF, New York Heart Association (NYHA) I-IV (66% NYHA III-IV), and left ventricular ejection fraction (LVEF) 26 +/- 9% (mean +/- SD) were studied with cardiac and renal catheterizations at baseline and followed for 5.5 +/- 3.7 years (median 5.5 years, range 12 days to 11.6 years). Nineteen deaths and 13 cases of heart transplantation were registered. Only renal NA spillover above median, 1.19 (interquartile range 0.77-1.43) nmol/min, was independently associated with an increased relative risk (RR) of the combined endpoint (RR 3.1, 95% CI 1.2-7.6, P = 0.01) in a model also including total body NA spillover, LVEF, glomerular filtration rate (GFR), renal blood flow, cardiac index, aetiology, and age. Conclusion Renal noradrenergic activation has a strong negative predictive value on outcome independent of overall sympathetic activity, GFR, and WEE These findings suggest that treatment regimens that further reduce renal noradrenergic stimulation could be advantageous by improving survival in patients with CHF.
引用
收藏
页码:906 / 913
页数:8
相关论文
共 39 条
[1]  
Amann K, 2000, J AM SOC NEPHROL, V11, P1469, DOI 10.1681/ASN.V1181469
[2]   Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT) [J].
Anand, IS ;
Fisher, LD ;
Chiang, YT ;
Latini, R ;
Masson, S ;
Maggioni, AP ;
Glazer, RD ;
Tognoni, G ;
Cohn, JN .
CIRCULATION, 2003, 107 (09) :1278-1283
[3]   Sympathetic discharge to mesenteric organs and the liver - Evidence for substantial mesenteric organ norepinephrine spillover [J].
Aneman, A ;
Eisenhofer, G ;
Olbe, L ;
Dalenback, J ;
Nitescu, P ;
Fandriks, L ;
Friberg, P .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (07) :1640-1646
[4]  
BRUN C, 1951, J LAB CLIN MED, V37, P955
[5]   RENAL AFFERENT DENERVATION PREVENTS HYPERTENSION IN RATS WITH CHRONIC-RENAL-FAILURE [J].
CAMPESE, VM ;
KOGOSOV, E .
HYPERTENSION, 1995, 25 (04) :878-882
[6]   RENAL AFFERENT DENERVATION PREVENTS THE PROGRESSION OF RENAL-DISEASE IN THE RENAL ABLATION MODEL OF CHRONIC-RENAL-FAILURE IN THE RAT [J].
CAMPESE, VM ;
KOGOSOV, E ;
KOSS, M .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 26 (05) :861-865
[7]   PLASMA NOREPINEPHRINE AS A GUIDE TO PROGNOSIS IN PATIENTS WITH CHRONIC CONGESTIVE HEART-FAILURE [J].
COHN, JN ;
LEVINE, TB ;
OLIVARI, MT ;
GARBERG, V ;
LURA, D ;
FRANCIS, GS ;
SIMON, AB ;
RECTOR, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (13) :819-823
[8]   SYMPATHETIC OVERACTIVITY IN PATIENTS WITH CHRONIC-RENAL-FAILURE [J].
CONVERSE, RL ;
JACOBSEN, TN ;
TOTO, RD ;
JOST, CMT ;
COSENTINO, F ;
FOUADTARAZI, F ;
VICTOR, RG .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (27) :1912-1918
[9]   POWER AND SAMPLE-SIZE CALCULATIONS - A REVIEW AND COMPUTER-PROGRAM [J].
DUPONT, WD ;
PLUMMER, WD .
CONTROLLED CLINICAL TRIALS, 1990, 11 (02) :116-128
[10]   REGIONAL RELEASE AND REMOVAL OF CATECHOLAMINES AND EXTRANEURONAL METABOLISM TO METANEPHRINES [J].
EISENHOFER, G ;
RUNDQUIST, B ;
ANEMAN, A ;
FRIBERG, P ;
DAKAK, N ;
KOPIN, IJ ;
JACOBS, MC ;
LENDERS, JWM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (10) :3009-3017